2. Search Result
Search Result
Results for "

estrogenic

" in MCE Product Catalog:

334

Inhibitors & Agonists

1

Screening Libraries

2

Peptides

55

Natural
Products

69

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas
  • HY-N8170
    4',2-Dihydroxy-4,6-dimethoxydihydrochalcone

    		Estrogen Receptor/ERR Endocrinology
    4',2-Dihydroxy-4,6-dimethoxydihydrochalcone, an estrogen agonist, shows binding affinity for bovine uterine estrogen receptor with an IC5050 of 15 μM.
  • HY-144204
    Estrogen receptor antagonist 5

    		Estrogen Receptor/ERR Cancer Endocrinology
    Estrogen receptor antagonist 5 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 5 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 165).
  • HY-144206
    Estrogen receptor antagonist 6

    		Estrogen Receptor/ERR Endocrinology
    Estrogen receptor antagonist 6 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 6 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 166).
  • HY-B1662
    Hexestrol

    		Estrogen Receptor/ERR Endocrinology
    Hexestrol is a nonsteroidal synthetic estrogen, with a Ki of 0.06 and 0.06 nM for estrogen receptor alpha (ERα) and ERβ. Hexestrol can be used for the research of the diseases caused by estrogen deficiencym, and it also can increase the weight of cattle.
  • HY-144138
    Estrogen receptor antagonist 2

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 2 is a selective estrogen receptor downregulator. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development. Estrogen receptor antagonist 2 has the potential for the research of breast cancer diseases (extracted from patent WO2021228210A1, compound 3).
  • HY-144137
    Estrogen receptor antagonist 1

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 1 is a selective estrogen receptor antagonist. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development. Estrogen receptor antagonist 1 has the potential for the research of breast cancer diseases (extracted from patent WO2021249533A1, compound 4).
  • HY-B0234
    Estrone

    E1; Oestrone

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estrone (E1) is a natural estrogenic hormone. Estrone is the main representative of the endogenous estrogens and is produced by several tissues, especially adipose tissue. Estrone is the result of the process of aromatization of androstenedione that occurs in fat cells.
  • HY-W326021
    Phenolphthalol

    		Others Endocrinology
    Phenolphthalol is a laxative in drug preparations and also estrogenically active.
  • HY-144139
    Estrogen receptor antagonist 3

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 3 is a potent antagonist of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. Estrogen receptor antagonist 3 has the potential for the research of cancer diseases (extracted from patent WO2021213358A1, compound 7).
  • HY-144202
    Estrogen receptor antagonist 4

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 4 is a potent antagonist of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. Estrogen receptor antagonist 4 has the potential for the research of cancer diseases (extracted from patent WO2021213358A1, compound 1).
  • HY-113293B
    Estrone sulfate sodium

    		Estrogen Receptor/ERR Endogenous Metabolite Cancer
    Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). strone sulfate can be used for the research of breast cancer.
  • HY-B1830
    Estradiol enanthate

    		Estrogen Receptor/ERR Endocrinology
    Estradiol enanthate is a shorter-acting estrogen. The combination of Estradiol enanthate and dihydroxyprogesterone acetophenide can be used as a monthly injectable contraceptive.
  • HY-129987
    Estradiol 17-(β-D-Glucuronide) (sodium)

    		Endogenous Metabolite Endocrinology Metabolic Disease
    Estradiol 17-(β-D-Glucuronide) sodium, a metabolite of estrogen, is well known to cause intrahepatic cholestasis in humans.
  • HY-135583
    LY88074 Trimethyl ether

    		Others Endocrinology
    LY88074 Trimethyl ether (Example 1) is useful for the inhibition of the various estrogen deficient conditions, which are associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia.
  • HY-14247B
    Fadrozole hydrochloride hemihydrate

    CGS 16949A hemihydrate; (Rac)-FAD286 hydrochloride hemihydrate

    		 Cytochrome P450 Cancer Endocrinology
    Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidal aromatase inhibitor, with an IC50 of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, with IC50 values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease and cancer.
  • HY-N9329
    Glicoricone

    		Monoamine Oxidase Estrogen Receptor/ERR Metabolic Disease
    Glicoricone, a phenolic compound, is isolated from a species of licorice. Glicoricone is an inhibitor of monoamine oxidase (MAO), with an IC50 of 140 μM. Glicoricone binds to estrogen receptor (ER) and shows estrogen antagonist activity.
  • HY-125703
    Ferutinin

    		Estrogen Receptor/ERR Apoptosis Cancer Infection Endocrinology Inflammation/Immunology
    Ferutinin, a natural terpenoid compound, is an estrogen receptor ERα agonist and estrogen ERβ-receptor agonist/antagonist with IC50s of 33.1 nM and 180.5 nM, respectively. Ferutinin acts as an electrogenic Ca 2+-ionophore that increases calcium permeability of lipid bilayer membranes, mitochondria. Ferutinin possesses estrogenic, antitumor, antibacterial and antiinflammatory activities.
  • HY-142926
    ER degrader 2

    		Estrogen Receptor/ERR Cancer
    ER degrader 2 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 2 has the potential for the research of cancer diseases (extracted from patent CN112830919A, compound 1).
  • HY-142925
    ER degrader 1

    		Estrogen Receptor/ERR Cancer
    ER degrader 1 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 1 has the potential for the research of cancer diseases (extracted from patent WO2021139756A1, compound 11).
  • HY-142927
    ER degrader 3

    		Estrogen Receptor/ERR Cancer
    ER degrader 3 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 3 has the potential for the research of cancer diseases (extracted from patent WO2018233591A1, compound 1).
  • HY-135588
    Raloxifene 6,4'-Bis-β-D-glucuronide

    		Drug Metabolite Metabolic Disease
    Raloxifene 6,4'-Bis-β-D-glucuronide (compound IV) is a metabolite of Raloxifene. Raloxifene is a selective estrogen receptor antagonist for the prevention of osteoporosis.
  • HY-14248
    Letrozole

    CGS 20267

    		 Cytochrome P450 Autophagy Cancer
    Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer.
  • HY-133189
    Bis-propargyl-PEG9

    		PROTAC Linkers Endocrinology
    Bis-propargyl-PEG9 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG9 can be used to synthesize the bivalent estrogen receptor ligands.
  • HY-145341
    GNE-149

    		Estrogen Receptor/ERR Cancer
    GNE-149 is an orally bioavailable full antagonist of estrogen receptor α (ERα; IC50=0.053 nM). GNE-149 is a selective estrogen receptor degrader (SERD). GNE-149 can be used for the research of breast cancer.
  • HY-13556
    Arzoxifene

    LY353381; SERM III

    		 Estrogen Receptor/ERR Metabolic Disease
    Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator with a fixed ring structure similar to raloxifene. Arzoxifene has minimal side effects with powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile.
  • HY-132294
    GNE-502

    		Estrogen Receptor/ERR Cancer
    GNE-502 is an orally active and potent degrader for estrogen receptor (ER). GNE-502 can be used for the research of breast cancer.
  • HY-131122S
    4-Nonylphenol-D5

    4-n-Nonylphenol-2,3,5,6-d4,OD

    		 Estrogen Receptor/ERR Others
    4-Nonylphenol-d5 is the deuterium labeled 4-Nonylphenol. 4-Nonylphenol, a major degradation product of Nonylphenol ethoxylates (NPEOs), is a persistent organic pollutant with endocrine-disrupting properties and exerts estrogenic activity[1].
  • HY-138642
    Vepdegestrant

    ARV-471

    		 Estrogen Receptor/ERR PROTACs Cancer
    Vepdegestrant (ARV-471) is an oral estrogen receptor PROTAC protein degrader for breast cancer. Vepdegestrant is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex. Vepdegestrant leads to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant robustly degrades ER in ER-positive breast cancer cell lines with a half-maximal degradation concentration (DC50) of ~2 nM.
  • HY-135592
    LY88074 Methyl ether

    		Others Endocrinology
    LY88074 Methyl ether (Example 2) is useful for the inhibition of the various estrogen deficient conditions, which are associated with estrogendeprivation syndrome including osteoporosis and hyperlipidemia.
  • HY-119437
    FLTX1

    		Estrogen Receptor/ERR Cancer
    FLTX1 is a fluorescent Tamoxifen derivative that can specifically label intracellular Tamoxifen-binding sites (estrogen receptors) under permeabilized and non-permeabilized conditions. FLTX1 exhibits the potent antiestrogenic properties of Tamoxifen in breast cancer cells. FLTX1 is devoid of the estrogenic agonistic effect on the uterus.
  • HY-101119
    GLL398

    		Estrogen Receptor/ERR Cancer
    GLL398, an orally active selective estrogen receptor degrader (SERD), competitively binds to the estrogen receptor with an IC50 value of 1.14 nM. GLL398 exhibits a strong dose-dependent binding profile for the ER with a Y537S point mutation (IC50= 29.5 nM). GLL398 blocks tumor growth in xenograft breast cancer models.
  • HY-143226
    DK1

    		Estrogen Receptor/ERR Metabolic Disease
    DK1 is a potent modulator of estrogen related receptor. DK1 has an ability in reducing blood glucose, and impacts the activity of ERRα receptor. DK1 has the potential for the research of diabetes.
  • HY-13757A
    Tamoxifen

    ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 µM and 1.8 µM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse.
  • HY-13757
    Tamoxifen Citrate

    ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 µM and 1.8 µM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis.Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse.
  • HY-16950
    4-Hydroxytamoxifen

    (Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen; (Z)-Afimoxifene

    		 Estrogen Receptor/ERR Cancer
    4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) induces CRISPR/Cas9 systems based on ER mediated nucleus translocation.
  • HY-105184
    YM511

    		Cytochrome P450 Endocrinology
    YM511 is a highly specific non-steroidal aromatase inhibitor. YM511 inhibits aromatase activities in microsomes from rat ovary and human placenta competitively (IC50s of 0.4 and 0.12 nM, respectively). YM511 slightly inhibits production of other steroid hormones. YM511 has the potential for suppressing estrogen-dependent action research without affecting serum levels of other steroid hormones.
  • HY-N1581
    Quassin

    Nigakilactone D

    		 Parasite Infection Endocrinology
    Quassin (Nigakilactone D) is a bioactive triterpenoid from stem bark extract of Quassia amara. Quassin inhibits P. falciparum with an IC50 of 0.15 μM. Quassin possesses reversible antifertility, anti-estrogenic and anti-plasmodial activity.
  • HY-110157
    AC-186

    		Estrogen Receptor/ERR Neurological Disease
    AC-186 is a selective non-steroidal estrogen receptor β (ERβ) agonist with EC50s of 6 nM and 5000 nM for ERβ and ERα, respectively. AC-186 shows gender specific neuroprotection in a Parkinson’s Disease rat model.
  • HY-13757AS
    Tamoxifen-​d5

    ICI 47699-​d5; (Z)-Tamoxifen-d5; trans-Tamoxifen-d5

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen-d5 is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity[1][2].
  • HY-12452
    DPN

    Diarylpropionitrile

    		 Estrogen Receptor/ERR Apoptosis Autophagy Neurological Disease
    DPN (Diarylpropionitrile) is a non-steroidal estrogen receptor β (ERβ) selective ligand, with an EC50 of 0.85 nM. DPN has neuroprotective effects in a number of neurological diseases.
  • HY-139999
    LCL-PEG3-N3

    		Ligands for E3 Ligase Cancer
    LCL-PEG3-N3 is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor.
  • HY-139999A
    LCL-PEG3-N3 hydrochloride

    		Ligands for E3 Ligase Cancer
    LCL-PEG3-N3 (hydrochloride) is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor.
  • HY-151199
    Steroid sulfatase/17β-HSD1-IN-1

    		Others Cancer Endocrinology
    Steroid sulfatase/17β-HSD1-IN-1 is a potent steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor with an IC50 value of 28 nM for cellular human steroid sulfatase. Steroid sulfatase/17β-HSD1-IN-1 can be used to research estrogen-dependent diseases.
  • HY-118861
    Enclomiphene

    (E)-Clomiphene; trans-Clomiphene; Enclomifene

    		 Estrogen Receptor/ERR Endocrinology Metabolic Disease
    Enclomiphene ((E)-Clomiphene) is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes.
  • HY-118861B
    Enclomiphene hydrochloride

    (E)-Clomiphene hydrochloride; trans-Clomiphene hydrochloride; Enclomifene hydrochloride

    		 Estrogen Receptor/ERR Endocrinology Metabolic Disease
    Enclomiphene ((E)-Clomiphene) hydrochloride is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene hydrochloride can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes.
  • HY-19822
    Elacestrant

    RAD1901

    		 Estrogen Receptor/ERR Cancer
    Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo.
  • HY-19822A
    Elacestrant dihydrochloride

    RAD1901 dihydrochloride

    		 Estrogen Receptor/ERR Cancer
    Elacestrant (RAD1901) dihydrochloride is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo.
  • HY-W009300
    4-Hydroxyestrone

    4-OHE1

    		 Endogenous Metabolite Neurological Disease
    4-Hydroxyestrone (4-OHE1), an estrone metabolite, has strong neuroprotective effect against oxidative neurotoxicity. 4-Hydroxyestrone increases cytoplasmic translocation of p53 resulting from SIRT1-mediated deacetylation of p53. 4-Hydroxyestrone has little estrogenic activity.
  • HY-118861A
    Enclomiphene citrate

    (E)-Clomiphene citrate; trans-Clomiphene citrate; Enclomifene citrate

    		 Estrogen Receptor/ERR Endocrinology Metabolic Disease
    Enclomiphene ((E)-Clomiphene) citrate is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene citrate can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes.
  • HY-136092
    Androsta-1,4,6-triene-3,17-dione

    		Cytochrome P450 Endocrinology Neurological Disease
    Androsta-1,4,6-triene-3,17-dione is a lipophilic and specific aromatase inhibitor with a Ki of 0.18 μM. Androsta-1,4,6-triene-3,17-dione inhibits estrogen biosynthesis and shows antifertility effects. Androsta-1,4,6-triene-3,17-dione induces impairment of spatial memory.
  • HY-N6885
    Puerarin-4'-O-β-D-glucopyranoside

    		Others Cancer
    Puerarin-4'-O-β-D-glucopyranoside (compound 8) is a isoflavone from Pueraria lobata root (PLR). Puerarin-4'-O-β-D-glucopyranoside has estrogenic activity and anti-proliferation of MCF-7 human breast carcinoma cells.
  • HY-122416
    6,8-Diprenylnaringenin

    Lonchocarpol A; Senegalensin

    		 BCRP Cancer Metabolic Disease
    6,8-Diprenylnaringenin (Lonchocarpol A; Senegalensin), a hop prenylflavonoid, is a inhibitor of breast cancer resistance protein (BCRP/ABCG2). 6,8-Diprenylnaringenin inhibits ABCG2-mediated efflux of Mitoxantrone, and 3H-Methotrexate transport (IC50=0.41 μM) in HEK293 cells. 6,8-Diprenylnaringenin exhibits some estrogenicity, but its potency is less than 1% of that of 8-Prenylnaringenin.
  • HY-A0036
    Bazedoxifene acetate

    TSE-424 acetate

    		 Estrogen Receptor/ERR Cancer
    Bazedoxifene acetate (TSE-424 acetate) is an oral, nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene acetate can be used for the research of osteoporosis. Bazedoxifene acetate also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer.
  • HY-B0845
    Prochloraz

    BTS 40542

    		 Fungal Estrogen Receptor/ERR Androgen Receptor Aryl Hydrocarbon Receptor Infection Endocrinology
    Prochloraz is an imidazole antifungal. Prochloraz is as an estrogen receptor (ER) and androgen receptor (AR) antagonist and an aromatase inhibitor with IC50 values of 25 μM, 4 μM and 0.3 μM, respectively. Prochloraz is able to activate the aryl hydrocarbon receptor (AhR) having an EC50 of 1 μM.
  • HY-144070
    ErSO-DFP

    		Others Cancer
    ErSO-DFP is an anticipatory unfolded protein response (a-UPR) activator. ErSO-DFP has enhanced selectivity for estrogen receptor alpha-positive (ERα+) cancer cells with a wider selectivity window than ErSO.ErSO-DFP displays antitumor activity and leads to profound regression of MCF-7 tumors in mice model.
  • HY-A0031
    Bazedoxifene

    TSE-424

    		 Estrogen Receptor/ERR Cancer
    Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer.
  • HY-A0031A
    Bazedoxifene hydrochloride

    TSE-424 hydrochloride

    		 Estrogen Receptor/ERR Cancer
    Bazedoxifene hydrochloride (TSE-424 hydrochloride) is an oral active, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene hydrochloride can be used for the research of osteoporosis. Bazedoxifene hydrochloride acts as an inhibitor of IL-6/GP130 protein-protein interactions. Bazedoxifene hydrochloride can be used for the research of pancreatic cancer.
  • HY-150692
    Estrogen receptor α antagonist 1

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor α antagonist 1 (compound 35) is a highly selective antagonist of estrogen receptor α, with IC50s of 0.02, 6.55 and 7.73 μM for estrogen receptor α, estrogen receptor β and MCF-7 cells, respectively. Estrogen receptor α antagonist 1 can be used for the research of cancer.
  • HY-B2245
    Estradiol dipropionate

    		Estrogen Receptor/ERR Progesterone Receptor Endocrinology
    Estradiol dipropionate is a combined estrogen-progesterone, acts as an estrogen and progesterone agonist.
  • HY-13556A
    Arzoxifene hydrochloride

    LY353381 hydrochloride; SERM III hydrochloride

    		 Estrogen Receptor/ERR Cancer
    Arzoxifene (LY353381) hydrocloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.
  • HY-B1100
    Estradiol (cypionate)

    		Estrogen Receptor/ERR Endocrinology Cancer
    Estradiol cypionate is a 17 β-cyclopentylpropinate ester of estradiol, inhibits ET-1 synthesis via estrogen receptor IC50 value: Target: estrogen receptor Estradiol cypionate is a synthetic ester, is a estrogen.
  • HY-B1403
    Dienestrol

    		Estrogen Receptor/ERR Endocrinology Cancer
    Dienestrol is a synthetic, non-steroidal estrogen, is an estrogen receptor agonist, for the treatment of menopausal and postmenopausal symptoms.
  • HY-151744
    N3-TFBA-O2Oc

    		ADC Linker Others
    N3-TFBA-O2Oc is a click chemistry reagent containing an azide group and an aryl group. Aryl azides are well-known precursors of nitrenes and have been introduced by Fleet et al. as versatile photoaffinity labeling agents to probe biological receptors. This type of compounds has been used as photo-cross linker (λmax=258 nm) in estrogen receptor studies and for direct surface coating of carbon and organic based polymers.
  • HY-B0412
    Estriol

    Oestriol

    		 Estrogen Receptor/ERR Endogenous Metabolite Cancer
    Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.
  • HY-P3833
    Yp537

    		Estrogen Receptor/ERR Endocrinology
    Yp537 is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor.
  • HY-13738A
    Raloxifene hydrochloride

    Keoxifene hydrochloride; LY156758; LY139481 hydrochloride

    		 Estrogen Receptor/ERR Autophagy Endocrinology Cancer
    Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue.
  • HY-13738
    Raloxifene

    Keoxifene; LY156758 free base; LY139481

    		 Estrogen Receptor/ERR Cancer
    Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research.
  • HY-143253
    Estrogen receptor antagonist 7

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 7 (compound 13) is a potent estrogen receptors (ER) antagonist. Estrogen receptor antagonist 7 has antiproliferative activity against breast and ovarian cancer cells. Anticancer and anti-uterotrophic activities.
  • HY-15731
    Estetrol

    		Estrogen Receptor/ERR Endogenous Metabolite Cardiovascular Disease
    Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast.
  • HY-B0723
    Ospemifene

    FC-1271a

    		 Estrogen Receptor/ERR Cancer
    Ospemifene is a non-estrogen selective estrogen receptor modulator (SERM), with Kis of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene can be used for the research of vaginal atrophy and breast cancer.
  • HY-110201
    Estrogen receptor modulator 1

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors.
  • HY-B0412S1
    Estriol-d1

    		Estrogen Receptor/ERR Endogenous Metabolite Cancer
    Estriol-d is the deuterium labeled Estriol. Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.
  • HY-B1941
    4-tert-Octylphenol

    		Endogenous Metabolite Apoptosis Endocrinology Neurological Disease
    4-tert-Octylphenol, a endocrine-disrupting chemical, is an estrogenic drug. 4-tert-Octylphenol induces apoptosis in neuronal progenitor cells in offspring mouse brain. 4-tert-Octylphenol reduces bromodeoxyuridine (BrdU), mitotic marker Ki67, and phospho-histone H3 (p-Histone-H3), resulting in a reduction of neuronal progenitor proliferation. 4-tert-Octylphenol disrupts brain development and behavior in mice.
  • HY-N2448
    Lindleyin

    		Estrogen Receptor/ERR Endocrinology
    Lindleyin, isolated from Rhei rhizoma, mediates hormonal effects through estrogen receptors. Lindleyin binds to ERα with estrogenic activity.
  • HY-135312
    AZ'6421

    		Estrogen Receptor/ERR PROTACs Cancer
    AZ'6421 acts as Protcolysis Targeting Chimera (PROTAC) to selectively degrade estrogen receptor alpha. AZ'6421 has a potent anti-tumour effect to inhibit the uncontrolled cellular proliferation which arises from malignant disease. AZ'6421 can be used for the research of cancer such as breast cancer.
  • HY-13738S
    Raloxifene-d4

    		Estrogen Receptor/ERR Cancer
    Raloxifene-d4 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
  • HY-13738S2
    Raloxifene-d4 hydrochloride

    		Estrogen Receptor/ERR Cancer
    Raloxifene-d4 (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
  • HY-13738S3
    Raloxifene-d10

    		Estrogen Receptor/ERR Cancer
    Raloxifene-d10 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
  • HY-B0412S
    Estriol-d2

    		Estrogen Receptor/ERR Endogenous Metabolite Cancer
    Estriol-d2 is the deuterium labeled Estriol. Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.
  • HY-B0412S2
    Estriol-d3

    		Estrogen Receptor/ERR Endogenous Metabolite Cancer
    Estriol-d3 is the deuterium labeled Estriol. Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.
  • HY-15731S
    Estetrol-d4

    		Estrogen Receptor/ERR Endogenous Metabolite Cardiovascular Disease
    Estetrol-d4 is the deuterium labeled Estetrol. Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast[1][2].
  • HY-138690
    Estrogen receptor modulator 6

    		Estrogen Receptor/ERR Endocrinology
    Estrogen receptor modulator 6 (compound 3a) is a selective estrogen receptor (ER) β agonist (Ki=0.44 nM). Estrogen receptor modulator 6 displays 19-fold selectivity for ERβ over ERα(Ki=8.4 nM).
  • HY-113293BS
    Estrone sulfate-d5 sodium

    		Estrogen Receptor/ERR Endogenous Metabolite Cancer
    Estrone sulfate-d5 (sodium) is the deuterium labeled Estrone sulfate sodium. Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). strone sulfate can be used for the research of breast cancer[1][2].
  • HY-N6678
    Zearalanone

    		Estrogen Receptor/ERR Endocrinology
    Zearalenone is a nonsteroidal estrogenic mycotoxin produced by Fusarium species, which colonizes several grains. Zearalenone has low acute toxicity and carcinogenicity. Due to its agonistic effect on the estrogen receptor, Zearalenone exhibits distinct estrogenic and anabolic properties in several animal species, resulting in severe effects on the reproductive system.
  • HY-113293BS1
    Estrone sulfate-d4 sodium

    		Estrogen Receptor/ERR Endogenous Metabolite Cancer
    Estrone sulfate-d4 (sodium) is deuterium labeled Estrone sulfate (sodium). Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). strone sulfate can be used for the research of breast cancer[1][2].
  • HY-13738S4
    Raloxifene-d10-1

    Keoxifene-d10; LY156758(free base)-d10; LY139481-d10

    		 Estrogen Receptor/ERR Cancer
    Raloxifene-d10-1 is the deuterium labeled Raloxifene[1]. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[2].
  • HY-18719A
    Endoxifen Z-isomer hydrochloride

    		Estrogen Receptor/ERR Potassium Channel Cancer
    Endoxifen Z-isomer hydrochloride is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα).
  • HY-18719
    Endoxifen (Z-isomer)

    		Estrogen Receptor/ERR Potassium Channel Cancer
    Endoxifen Z-isomer is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα).
  • HY-B0412S3
    Estriol-13C3

    Oestriol-13C3

    		 Estrogen Receptor/ERR Endogenous Metabolite Cancer
    Estriol- 13C3 is the 13C-labeled Estriol. Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.
  • HY-100266
    Nitromifene

    CI628

    		 Estrogen Receptor/ERR Cancer
    Nitromifene is an antagonist of estrogen receptor (ER).
  • HY-150601
    Estrogen receptor-IN-1

    		Estrogen Receptor/ERR Metabolic Disease
    Estrogen receptor-IN-1 (compound 16) is a potent estrogen receptor (ER) inhibitor with IC50s of 13, 5µM for ERα and Erβ, respectively.
  • HY-16023B
    (Rac)-Acolbifene

    EM-343; (Rac)-EM-652

    		 Estrogen Receptor/ERR Cancer
    (Rac)-Acolbifene (EM-343; (Rac)-EM-652) is the racemic form of EM652 (estrogen receptor antagonist), has anti-estrogenic and estrogenic activities. (Rac)-Acolbifene (EM-343; (Rac)-EM-652) contains a piperidine ring, shows good pharmacological profile,relative binding affinity (RBA)=380.
  • HY-103450
    G36

    		Estrogen Receptor/ERR Endocrinology
    G-36 is a cell permeable non-steroidal antagonist of G-protein-coupled estrogen receptor (GPER/GPR30) which selectively inhibits estrogen-mediated activation of PI3K by GPER, but not by ERα. G-36 also inhibits estrogen-mediated calcium mobilization (IC50=112 nM).
  • HY-14589
    Chrysin

    5,7-Dihydroxyflavone

    		 Estrogen Receptor/ERR Cancer
    Chrysin is one of the most well known estrogen blockers.
  • HY-B0316
    Avobenzone

    		Estrogen Receptor/ERR Apoptosis Others
    Avobenzone, a dibenzoylmethane compound, is one of the most widely used filters in sunscreens for skin photoprotection in the UVA band. Avobenzone is an endocrine disruptor that directly binds to estrogen receptor β and acts as an estrogen agonist.
  • HY-150693
    Estrogen receptor β antagonist 2

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor β antagonist 2 is a potent and selective estrogen receptor β (ERβ) antagonist with IC50s of 109.10, 0.63 µM for Erα and Erβ, respectively.
  • HY-B0463
    Clomiphene citrate

    Clomifene citrate

    		 Estrogen Receptor/ERR Endocrinology
    Clomiphene citrate (Clomifene citrate) is a selective estrogen receptor modulator.
  • HY-U00216
    NNC45-0781

    		Estrogen Receptor/ERR Metabolic Disease
    NNC45-0781 is a tissue-selective estrogen partial-agonist.
  • HY-113293A
    Estrone sulfate potassium

    		Endogenous Metabolite Endocrinology Cancer
    Estrone sulfate potassium is a natural endogenous steroid and is an estrogen ester and conjugate.
  • HY-121236
    Bavachromene

    		Others Others
    Bavachromene is a chromenochalcone from the seeds of Psoralea corylifolia with estrogenic activities .
  • HY-135585
    LY88074

    		Others Endocrinology
    LY88074 (Compound 88074) is a Raloxifene analog lacking the basic side chain. Raloxifene is a selective estrogen receptor modulator, and reduces fracture risk at least in part by improving the mechanical properties of bone in a cell- and estrogen receptor-independent manner.
  • HY-B2158
    Chlorotrianisene

    		Estrogen Receptor/ERR COX Endocrinology Cardiovascular Disease
    Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood.
  • HY-12825
    BHPI

    		Estrogen Receptor/ERR Cancer
    BHPI is a potent inhibitor of nuclear estrogen–ERα-regulated gene expression; elicits sustained ERα-dependent activation of the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR), and persistent inhibition of protein synthesis.
  • HY-N0791
    Tectoridin

    		Estrogen Receptor/ERR Cancer
    Tectoridin is a isoflavone isolated from Maackia amurensis. Tectoridin is a phytoestrogen and activates estrogen and thyroid hormone receptors. Tectoridin exerts the estrogenic effects via ER-dependent genomic pathway and GPR30-dependent nongenomic pathway.
  • HY-B1353
    Paroxypropione

    4'-Hydroxypropiophenone

    		 Others Endocrinology
    Paroxypropione is a manufactured, nonsteroidal estrogen which has been used medically as an antigonadotropin.
  • HY-100583
    (-)-(S)-Equol

    		Estrogen Receptor/ERR Endogenous Metabolite Cancer Metabolic Disease Neurological Disease
    (-)-(S)-Equol is a high affinity ligand for estrogen receptor β with a Ki of 0.73 nM.
  • HY-N0553
    Gypenoside XVII

    Gynosaponin S

    		 Estrogen Receptor/ERR Endogenous Metabolite Cardiovascular Disease
    Gypenoside XVII, a novel phytoestrogen belonging to the gypenosides, can activate estrogen receptors.
  • HY-N0260
    Epmedin C

    Epimedin-C; Baohuoside-VI

    		 Others Inflammation/Immunology
    Epmedin C, a natural product, has estrogen-like effects for ovariectomized mice.
  • HY-B1405
    Dehydroisoandrosterone 3-acetate

    Dehydroepiandrosterone 3-acetate; DHEA acetate

    		 Androgen Receptor Endocrinology Cancer
    Dehydroepiandrosterone 3-acetate is a testosterone/estrogen precursor and known modulator of vertebrate aggression.
  • HY-14598
    Diethylstilbestrol

    Stilbestrol

    		 Estrogen Receptor/ERR Endocrinology Cancer
    Diethylstilbestrol (Stilbestrol), a synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders.
  • HY-138686
    GPR30 agonist-1

    		Estrogen Receptor/ERR Endocrinology Cardiovascular Disease
    GPR30 agonist-1 is a G protein-coupled receptor 30 (GPR30) agonist. GPR30 agonist-1 exerts vasorelaxant effects.
  • HY-135581
    Raloxifene 6-glucuronide

    		Estrogen Receptor/ERR Endocrinology
    Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression.
  • HY-135582
    Raloxifene 4'-glucuronide

    		Estrogen Receptor/ERR Endocrinology
    Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC50 of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression.
  • HY-128839
    PROTAC ERRα Degrader-2

    		PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ERRα Degrader-2 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-2 is an estrogen-related receptor alpha (ERRa) degrader.
  • HY-B1361
    Estropipate

    Piperazine estrone sulfate; Estrone sulfate piperazine salt

    		 Estrogen Receptor/ERR Endocrinology
    Estropipate is a form of estrogen, used to treat symptoms of menopause, also used to prevent osteoporosis.
  • HY-100327
    MK-6913

    Tetrahydrofluoroene 52

    		 Estrogen Receptor/ERR Metabolic Disease
    MK-6913 (Tetrahydrofluoroene 52) is a potent and selective estrogen receptor β agonist.
  • HY-113252
    2-Methoxyestrone

    		Endogenous Metabolite Metabolic Disease
    2-Methoxyestrone is a methoxylated catechol estrogen and metabolite of estrone, with a pKa of 10.81.
  • HY-U00178
    Idoxifene

    CB7432

    		 Estrogen Receptor/ERR Cancer
    Idoxifene (CB7432) is a novel tissue-specific selective estrogen receptor modulator (SERM).
  • HY-N2371
    27-Hydroxycholesterol

    		Estrogen Receptor/ERR LXR Endogenous Metabolite Cancer
    27-Hydroxycholesterol is a selective estrogen receptor modulator and an agonist of the liver X receptor.
  • HY-19468
    ERB-196

    WAY-202196

    		 Estrogen Receptor/ERR Inflammation/Immunology Neurological Disease
    ERB-196 is a nonsteroidal selective estrogen receptor-β (ERβ) agonist.
  • HY-122825
    SNIPER(ER)-110

    		SNIPERs Estrogen Receptor/ERR Cancer
    SNIPER(ER)-110 consists of a IAP ligand and an estrogen ligand, connected by a linker. SNIPER(ER)-51 induces estrogen receptor (ER) protein degradation with DC50s of <3 nM and 7.7 nM after 4 h and 48 h, respectively.
  • HY-B0234S1
    Estrone-d2

    E1-d2; Oestrone-d2

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estrone-d2 is the deuterium labeled Estrone. Estrone (E1) is a natural estrogenic hormone. Estrone is the main representative of the endogenous estrogens and is produced by several tissues, especially adipose tissue. Estrone is the result of the process of aromatization of androstenedione that occurs in fat cells[1][2].
  • HY-110392
    CMP8

    		Estrogen Receptor/ERR Cancer
    CMP8, a selective ligand for estrogen receptor, binds to the mutant estrogen receptor ligand binding domain (ERLBD). CMP8 exhibits IC50 values of 29 nM , 41 nM, 1100 nM and 2200 nM for MGERα, MGRERα, hERα and hERβ, respectively.
  • HY-128838
    PROTAC ERRα Degrader-1

    		PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an PROTAC estrogen-related receptor alpha (ERRa) degrader.
  • HY-B0234S2
    Estrone-d4

    E1-d4; Oestrone-d4

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estrone-d4 is the deuterium labeled Estrone. Estrone (E1) is a natural estrogenic hormone. Estrone is the main representative of the endogenous estrogens and is produced by several tissues, especially adipose tissue. Estrone is the result of the process of aromatization of androstenedione that occurs in fat cells[1][2].
  • HY-B0234S4
    Estrone-d2-1

    E1-d2-1; Oestrone-d2-1

    		 Estrogen Receptor/ERR Endogenous Metabolite
    Estrone-d2-1 is the deuterium labeled Estrone. Estrone (E1) is a natural estrogenic hormone. Estrone is the main representative of the endogenous estrogens and is produced by several tissues, especially adipose tissue. Estrone is the result of the process of aromatization of androstenedione that occurs in fat cells[1][2].
  • HY-100689
    Propyl pyrazole triol

    PPT

    		 Estrogen Receptor/ERR Cancer
    Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%).
  • HY-121351
    Inokosterone

    		Estrogen Receptor/ERR Inflammation/Immunology
    Inokosterone is a potential drug target of estrogen receptor 1 in rheumatoid arthritis patients.
  • HY-B0234S
    Estrone-13C3

    E1-13C3; Oestrone-13C3

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estrone- 13C3 is the 13C-labeled Estrone. Estrone (E1) is a natural estrogenic hormone. Estrone is the main representative of the endogenous estrogens and is produced by several tissues, especially adipose tissue. Estrone is the result of the process of aromatization of androstenedione that occurs in fat cells[1][2].
  • HY-B0234S3
    Estrone-13C2

    E1-13C2; Oestrone-13C2

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estrone- 13C2 is the 13C-labeled Estrone. Estrone (E1) is a natural estrogenic hormone. Estrone is the main representative of the endogenous estrogens and is produced by several tissues, especially adipose tissue. Estrone is the result of the process of aromatization of androstenedione that occurs in fat cells[1][2].
  • HY-B2158S
    Chlorotrianisene-d9

    		Estrogen Receptor/ERR COX Endocrinology Cardiovascular Disease
    Chlorotrianisene-d9 is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood[1][2][3].
  • HY-131404
    TPBM

    		Estrogen Receptor/ERR Cancer
    TPBM is a potent estrogen receptor α (ERα) inhibitor with an IC50 value of 9 μM for 17β-estradiol (E2)-ERα. TPBM reduces E2·ERα recruitment to an endogenous estrogen-responsive gene. TPBM inhibits E2-dependent growth of ERα-positive cancer cells (IC50=5 μM). TPBM is not toxic to cells and does not affect estrogen-independent cell growth.
  • HY-13724B
    Pipendoxifene hydrochloride

    		Estrogen Receptor/ERR Cancer
    Pipendoxifene hydrochloride is a selective estrogen receptor modulator (SERM) that can be used for the research of breast cancer.
  • HY-107245
    Segetalin B

    		Estrogen Receptor/ERR Metabolic Disease
    Segetalin B, a cyclopentapeptide from Vaccaria segetalis, possesses estrogen-like activity.
  • HY-143227
    DK3

    		Estrogen Receptor/ERR Metabolic Disease
    DK3 is a potent and selective estrogen-related receptor alpha (ERRα) agonist.
  • HY-111486
    LSZ-102

    		Estrogen Receptor/ERR Cancer
    LSZ-102 is a potent, orally bioavailable selective estrogen receptor degrader with an IC50 of 0.2 nM.
  • HY-B1012
    Quinestrol

    W-3566

    		 Estrogen Receptor/ERR Endocrinology Cancer
    Quinestrol is a synthetic estrogen, used in hormone replacement therapy, and occasionally to treat breast cancer and prostate cancer
  • HY-101271
    WAY-200070

    		Estrogen Receptor/ERR Neurological Disease
    WAY-200070 is a selective estrogen receptor β (ERRβ) agonist with an IC50 of 2.3 nM.
  • HY-B0316S
    Avobenzone-13C,d3

    		Estrogen Receptor/ERR Apoptosis Others
    Avobenzone- 13C,d3 is the 13C- and deuterium labeled Avobenzone. Avobenzone, a dibenzoylmethane compound, is one of the most widely used filters in sunscreens for skin photoprotection in the UVA band. Avobenzone is an endocrine disruptor that directly binds to estrogen receptor β and acts as an estrogen agonist[1][2].
  • HY-B0723S
    Ospemifene D4

    FC-1271a d4

    		 Estrogen Receptor/ERR Cancer
    Ospemifene-d4 is a deuterium labeled Ospemifene. Ospemifene is a selective and orally active estrogen receptor modulator for the prevention of osteoporosis with IC50 values of 827 nM and 1633 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene has bone-sparing, antitumor, and cholesterol-lowering effects[1][2].
  • HY-128793
    trans-Stilbene

    (E)-Stilbene

    		 Fluorescent Dye Others
    trans-Stilbene ((E)-Stilbene) is used in the manufacturing of dye lasers, optical brighteners, non-steroidal synthetic estrogens.
  • HY-112627
    CAY 10465

    		Aryl Hydrocarbon Receptor Cardiovascular Disease
    CAY 10465 is a selective and high-affinity AhR agonist, with a Ki of 0.2 nM, and shows no effect on estrogen receptor (Ki >100000 nM).
  • HY-135324
    4,4'-Iminodiphenol

    		Estrogen Receptor/ERR Endocrinology
    4-Propionamidophenol (compound 4a) is an inactive estrogen receptor ligand based on the diphenylamine skeleton.
  • HY-N7128
    Flavanone

    		Cytochrome P450 Cancer
    Flavanone is a naturally occurring flavone. Flavanone has inhibitory activity for human estrogen synthetase (aromatase).
  • HY-13636B
    Fulvestrant (R enantiomer)

    ICI 182780 (R enantiomer); ZD 9238 (R enantiomer); ZM 182780 (R enantiomer)

    		 Estrogen Receptor/ERR Cancer
    Fulvestrant R enantiomer (ICI 182780 R enantiomer) is the R enantiomer of Fulvestrant. Fulvestrant is a potent estrogen receptor antagonist with an IC50 of 9.4 nM.
  • HY-130046
    16-Epiestriol

    16-epi-Estriol; 16β,17β-Estriol

    		 Bacterial Infection Inflammation/Immunology
    16-Epiestriol is a metabolite of the endogenous estrogen estrone with antibacterial and anti-inflammatory effects[1][2][3].
  • HY-13636A
    Fulvestrant (S enantiomer)

    ICI 182780 (S enantiomer); ZD 9238 (S enantiomer); ZM 182780 (S enantiomer)

    		 Estrogen Receptor/ERR Cancer
    Fulvestrant S enantiomer (ICI 182780 S enantiomer) is the S enantiomer of Fulvestrant. Fulvestrant is a potent estrogen receptor antagonist with an IC50 of 9.4 nM.
  • HY-135581S1
    Raloxifene 6-glucuronide-d4 lithium

    		Estrogen Receptor/ERR Endocrinology
    Raloxifene 6-glucuronide-d4 (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[1][2][3].
  • HY-135582S1
    Raloxifene 4'-glucuronide-d4 lithium

    		Estrogen Receptor/ERR Endocrinology
    Raloxifene 4'-glucuronide-d4 (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC50 of 370 μM. [1][2]. Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[3].
  • HY-126109
    (±)-8-Prenylnaringenin

    		Estrogen Receptor/ERR Apoptosis Cancer Endocrinology Metabolic Disease
    (±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen Receptor/ERR) that inhibits ERα and ERβ with IC50s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research.
  • HY-135580A
    Raloxifene Bismethyl Ether hydrochloride

    		Drug Metabolite Endocrinology
    Raloxifene Bismethyl Ether hydrochloride is a metabolite of Raloxifene and an estrogen receptor inactive compound on which both hydroxyl groups are absent.
  • HY-135580
    Raloxifene Bismethyl Ether

    		Drug Metabolite Endocrinology
    Raloxifene Bismethyl Ether is a metabolite of Raloxifene and an estrogen receptor inactive compound on which both hydroxyl groups are absent.
  • HY-B0141A
    Alpha-Estradiol

    Alfatradiol; Epiestradiol; Epiestrol

    		 5 alpha Reductase Endogenous Metabolite Bacterial Inflammation/Immunology
    Alpha-Estradiol is a weak estrogen and a 5α-reductase inhibitor which is used as a topical medication in the treatment of androgenic alopecia.
  • HY-146424
    OBHS

    		Estrogen Receptor/ERR Cancer Neurological Disease
    OBHS is an estrogen receptor α (ERα) inhibitor. OBHS can also be used as a blowing agent.
  • HY-111845
    Estrone-N-O-C1-amido

    ERα ligand 1

    		 Estrogen Receptor/ERR Ligands for Target Protein for PROTAC Cancer
    Estrone-N-O-C1-amido (ERα ligand 1) is an Estrone-based estrogen ligand, which targets estrogen receptor α (ERα). Estrone-N-O-C1-amido (ERα ligand 1) binds to cIAP1 ligand Bestatin via a linker to form SNIPER.
  • HY-B1089
    Ethynodiol diacetate

    Ethynodiol acetate

    		 Progesterone Receptor Endocrinology
    Ethynodiol diacetate (Ethynodiol acetate) is a steroidal progestin which is used as a hormonal contraceptive, it has relatively little or no potency as an androgen,has significant estrogenic effects.
  • HY-117153
    GW7604

    		Estrogen Receptor/ERR Cancer
    GW7604 is an antiestrogen. GW7604 is the metabolite of GW5638, which is a high affinity estrogen receptor (ER) antagonist.
  • HY-111484
    GDC-0927

    SRN-927

    		 Estrogen Receptor/ERR Cancer
    GDC-0927 (SRN-927) is a potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonist.
  • HY-12864
    Brilanestrant

    ARN-810; GDC-0810

    		 Estrogen Receptor/ERR Cancer
    Brilanestrant (ARN-810; GDC-0810) is an orally bioavailable selective estrogen receptor degrader (SERD) with IC50 of 0.7 nM.
  • HY-128838A
    (rel)-PROTAC ERRα Degrader-1

    		Estrogen Receptor/ERR Others
    (rel)-PROTAC ERRα Degrader-1 is a relative configuration of PROTAC ERRα Degrader-1. PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an estrogen-related receptor alpha (ERRa) degrader.
  • HY-16950B
    (E)-4-Hydroxytamoxifen

    (E)-Afimoxifene

    		 Estrogen Receptor/ERR Cancer
    (E)-4-Hydroxytamoxifen ((E)-Afimoxifene), the less active isomer of (Z)-4-hydroxytamoxifen, is an estrogen receptor modulator.
  • HY-135593
    LY88074 analog 1

    		Others Endocrinology
    LY88074 analog 1 is a benzothiophene compound with nitrogen-containing non-basic side chains, Compound 26, extracted from patent EP0747380A1. LY88074 analog 1 is an agent for alleviating the symptoms of post-menopausal symptoms, such as osteoporosis, cardiovascular related pathological conditions, and estrogen-dependent cancer. LY88074 analog 1 can be used alone or in combination with estrogen or progestin.
  • HY-103456
    PHTPP

    		Estrogen Receptor/ERR Cancer
    PHTPP is a selective estrogen receptor β (ERβ) antagonist with 36-fold selectivity over ERα.
  • HY-N0012
    Glycitin

    Glycitein 7-O-β-glucoside

    		 Influenza Virus Bacterial Cancer Infection
    Glycitin is a natural isoflavone isolated from legumes; promotes the proliferation of bone marrow stromal cells and osteoblasts and suppresses bone turnover.Glycitin is antibacterial, antiviral and estrogenic.
  • HY-B0672
    Estradiol valerianate

    β-Estradiol 17-valerate

    		 Estrogen Receptor/ERR Endocrinology Cancer
    Estradiol valerianate (β-estradiol 17-valerate) is a synthetic estrogen widely used in combination with other steroid hormones in hormone replacement therapy drugs.
  • HY-B0216
    Ethynyl Estradiol

    17α-Ethynylestradiol; Ethynylestradiol

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Ethynyl Estradiol (17α-Ethynylestradiol;Ethynylestradiol) is an orally bio-active estrogen used in almost all modern formulations of combined oral contraceptive pills.
  • HY-108293
    Promestriene

    		Estrogen Receptor/ERR Cancer Endocrinology
    Promestriene is a synthetic diethyl-ether of estradiol and a locally effective estrogen. Promestriene has an efficient action on vaginal atrophy while it is minimally absorbed.
  • HY-N3943
    Glabrene

    		Tyrosinase Neurological Disease
    Glabrene, an isoflavene derived from licorice root, shows estrogen-like activity. Glabrene is a tyrosinase inhibitor with an IC50 of 3.5 μM.
  • HY-116896
    LY117018

    		Estrogen Receptor/ERR Cancer
    LY117018, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 exerts antiproliferative effects on breast cancer cell lines.
  • HY-103449
    G15

    		Estrogen Receptor/ERR Cancer
    G15 is a high affinity and selective G-protein-coupled estrogen receptor (GPER/GPR30) antagonist with a Ki of 20 nM.
  • HY-14598S
    Diethylstilbestrol-d8

    Stilbestrol-d8

    		 Estrogen Receptor/ERR Endocrinology Cancer
    Diethylstilbestrol-d8 is the deuterium labeled Diethylstilbestrol. Diethylstilbestrol (Stilbestrol), a synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders[1][2].
  • HY-B0891
    17α-Hydroxyprogesterone

    17-Hydroxyprogesterone; 17-OHP

    		 Progesterone Receptor Endogenous Metabolite Others
    17α-Hydroxyprogesterone (17-Hydroxyprogesterone) is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones, including the corticosteroids and the androgens and the estrogens.
  • HY-14247
    Fadrozole hydrochloride

    CGS 16949A; (Rac)-FAD286 hydrochloride

    		 Cytochrome P450 Cancer Endocrinology
    Fadrozole hydrochloride (CGS 16949A) is a potent, selective and nonsteroidal inhibitor of aromatase with an IC50 of 6.4 nM.
  • HY-13757AS1
    Tamoxifen-d3

    ICI 47699-d3; (Z)-Tamoxifen-d3; trans-Tamoxifen-d3

    		 Estrogen Receptor/ERR Apoptosis Autophagy HSP Cancer
    Tamoxifen-d3 is the deuterium labeled Tamoxifen[1]. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[2][3][4]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[6]. Tamoxifen activates autophagy and induces apoptosis[5]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[7].
  • HY-N0377
    Liquiritigenin

    4',7-Dihydroxyflavanone

    		 Estrogen Receptor/ERR Cancer Inflammation/Immunology Neurological Disease
    Liquiritigenin, a flavanone isolated from Glycyrrhiza uralensis, is a highly selective estrogen receptor β (ERβ) agonist with an EC50 of 36.5 nM for activation of the ERE tk-Luc.
  • HY-12870A
    AZD9496 maleate

    		Estrogen Receptor/ERR Cancer
    AZD9496 maleate is a potent and selective estrogen receptor (ERα) antagonist with IC50 of 0.28 nM. AZD9496 maleate is an orally bioavailable selective oestrogen receptor degrader (SERD).
  • HY-12870
    AZD9496

    		Estrogen Receptor/ERR Cancer
    AZD9496 is a potent and selective estrogen receptor (ERα) antagonist with an IC50 of 0.28 nM. AZD9496 is an orally bioavailable selective oestrogen receptor degrader (SERD).
  • HY-N5103
    Genistein 7,4'-di-O-β-D-glucoside

    		Others Endocrinology
    Genistein 7,4'-di-O-β-D-glucoside is a natural product with significantly estrogenic proliferative effect in MCF-7 cells.
  • HY-111484A
    GDC-0927 Racemate

    SRN-927 Racemate

    		 Estrogen Receptor/ERR Cancer
    GDC-0927 Racemate (SRN-927 Racemate) is a degrader of estrogen receptor, potently inhibits ER-α activity, with an IC50 of 0.2 nM, and is used in the research of ER-related diseases.
  • HY-141551B
    (R)-GNE-274

    		Others Others
    (R)-GNE-274 is a enantiomer of GNE-274. GNE-274 is a non-degrader that is structurally related to GDC-0927 (estrogen receptor degrader).
  • HY-N0233
    Bavachin

    Corylifolin

    		 Estrogen Receptor/ERR Cancer
    Bavachin, a flavonoid first isolated from seeds of P. corylifolia, acts as a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC50s of 320 and 680 nM, respectively.
  • HY-113252S2
    2-Methoxyestrone-d4

    		Endogenous Metabolite Inflammation/Immunology
    2-Methoxyestrone-d4 is the deuterium labeled 2-Methoxyestrone. 2-Methoxyestrone is a methoxylated catechol estrogen and metabolite of estrone, with a pKa of 10.81[1].
  • HY-N6741
    β-Zearalenol

    		Others Infection Endocrinology
    β-Zearalenol is a non-steroidal estrogenic mycotoxin synthesized by Fusarium species. β-Zearalenol potentially influences transcription and effects gene expression on translational level.
  • HY-113252S1
    2-Methoxyestrone-13C6

    		Endogenous Metabolite Metabolic Disease
    2-Methoxyestrone- 13C6 is the 13C-labeled 2-Methoxyestrone. 2-Methoxyestrone is a methoxylated catechol estrogen and metabolite of estrone, with a pKa of 10.81.
  • HY-124489
    2-Hydroxyestradiol

    		Endogenous Metabolite Metabolic Disease
    2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity.
  • HY-18719B
    Endoxifen hydrochloride

    		Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study.
  • HY-18295
    Erteberel

    LY500307

    		 Estrogen Receptor/ERR Neurological Disease
    Erteberel (LY500307) is a potent and selective estrogen receptor beta (ERβ) agonist with Ki and EC50 of 1.54 nM and 3.61 nM, respectively. Anti-tumor activities.
  • HY-136255
    Camizestrant

    AZD-9833

    		 Estrogen Receptor/ERR Cancer
    Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER + HER2-advanced breast cancer.
  • HY-18719E
    Endoxifen

    		Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study.
  • HY-114411
    ERRγ Inverse Agonist 1

    		Estrogen Receptor/ERR Cancer
    ERRγ Inverse Agonist 1 (Compound 12) is a potent, selective and orally bioavailable Estrogen-related Receptor grammar (ERRγ) inverse agonist, with an IC50 of 40 nM.
  • HY-117726
    WAY-169916

    		Estrogen Receptor/ERR NF-κB Inflammation/Immunology
    WAY-169916 is a pathway-selective ligand of ER (estrogen receptor) that acts by inhibiting NF-kB transcriptional activity. WAY-169916 has potent anti-inflammatory effect.
  • HY-N6710
    α-Zearalenol

    		Estrogen Receptor/ERR Inflammation/Immunology
    α-Zearalenol is a Mycotoxin with high affinity for the estrogen receptors (ER), α-Zearalenol is the derivative of zearalenone (ZEN), causes reproductive disorders in animals, due to its xenoestrogenic effects.
  • HY-137449
    Rintodestrant

    G1T48

    		 Estrogen Receptor/ERR CDK Cancer
    Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a CDK4/6 inhibitor.
  • HY-W087008
    7-Hydroxyflavanone

    		Cytochrome P450 Cancer Endocrinology
    7-Hydroxyflavanone is a potent inhibitor of aromatase (CYP19) activity with the IC50 of 65 μM. 7-Hydroxyflavanone exerts various biological effects, including anticarcinogenic, antioxidant and (anti-)estrogenic effects, and modula
  • HY-147402
    Taragarestrant

    D-0502

    		 Estrogen Receptor/ERR Cancer
    Taragarestrant (D-0502) is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant shows potent activity in various ER+ breast cancer cell lines and xenograft models.
  • HY-B0141AS
    Alpha-Estradiol-d3

    Alfatradiol-d3; Epiestradiol-d3; Epiestrol-d3

    		 Endogenous Metabolite 5 alpha Reductase Inflammation/Immunology
    Alpha-Estradiol-d3 is the deuterium labeled Alpha-Estradiol. Alpha-Estradiol is a weak estrogen and a 5α-reductase inhibitor which is used as a topical medication in the treatment of androgenic alopecia.
  • HY-113252S
    2-Methoxyestrone-13C,d3

    		Endogenous Metabolite Metabolic Disease
    2-Methoxyestrone- 13C,d3 is the 13C- and deuterium labeled 2-Methoxyestrone. 2-Methoxyestrone is a methoxylated catechol estrogen and metabolite of estrone, with a pKa of 10.81.
  • HY-19822B
    Elacestrant S enantiomer dihydrochloride

    RAD1901 S enantiomer dihydrochloride

    		 Estrogen Receptor/ERR Cancer
    Elacestrant S enantiomer dihydrochloride (RAD1901 S enantiomer dihydrochloride) is an low activity enantiomer of elacestrant dihydrochloride. Elacestrant (RAD1901) dihydrochloride is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.
  • HY-U00425
    PROTAC ERRα ligand 1

    		Estrogen Receptor/ERR Cancer
    PROTAC ERRα ligand 1 is an estrogen-related receptor α (ERRα) antagonist with IC50s of 0.04 and 2.8 μM for ERRα and ERRγ, respectively.
  • HY-N7501
    Isoformononetin

    		Others Metabolic Disease Inflammation/Immunology
    Isoformononetin is an analog of Daidzein (HY-N0019) and has immunoprotective effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions.
  • HY-112596A
    H3B-6545 hydrochloride

    		Estrogen Receptor/ERR Cancer
    H3B-6545 hydrochloride is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer.
  • HY-112596
    H3B-6545

    		Estrogen Receptor/ERR Cancer
    H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer.
  • HY-N0250
    Saikosaponin D

    		STAT NF-κB Estrogen Receptor/ERR Bacterial Cancer Infection Inflammation/Immunology
    Saikosaponin D is a triterpene saponin isolated from Bupleurum, with anti-inflammatory, anti-bacterial, anti-tumor, and anti-allergic activities; Saikosaponin D inhibits selectin, STAT3 and NF-kB and activates estrogen receptor-β.
  • HY-19498
    WAY-204688

    SIM-688

    		 NF-κB Inflammation/Immunology
    WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC50 of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.
  • HY-147402A
    Taragarestrant meglumine

    D-0502 meglumine

    		 Estrogen Receptor/ERR Cancer
    Taragarestrant (D-0502) meglumine is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant meglumine shows potent activity in various ER+ breast cancer cell lines and xenograft models.
  • HY-B0141AS1
    Alpha-Estradiol-d2

    Alfatradiol-d2; Epiestradiol-d2; Epiestrol-d2

    		 5 alpha Reductase Endogenous Metabolite Metabolic Disease Cardiovascular Disease
    Alpha-Estradiol-d2 is the deuterium labeled Alpha-Estradiol. Alpha-Estradiol is a weak estrogen and a 5α-reductase inhibitor which is used as a topical medication in the treatment of androgenic alopecia[1].
  • HY-13702
    Nilutamide

    Nilandron; RU 23908

    		 Androgen Receptor Parasite Cancer Infection Endocrinology
    Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties.
  • HY-B0672S1
    Estradiol valerianate-d4

    β-Estradiol 17-valerate-d4

    		 Estrogen Receptor/ERR Endocrinology Cancer
    Estradiol valerianate-d4 is the deuterium labeled Estradiol valerianate. Estradiol valerianate (β-estradiol 17-valerate) is a synthetic estrogen widely used in combination with other steroid hormones in hormone replacement therapy drugs.
  • HY-16950A
    (E/Z)-4-Hydroxytamoxifen

    Afimoxifene

    		 Estrogen Receptor/ERR Endogenous Metabolite Cancer
    (E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is an estrogen receptor modulator.
  • HY-19822D
    Elacestrant (S enantiomer)

    RAD1901 S enantiomer

    		 Estrogen Receptor/ERR Cancer
    Elacestrant S enantiomer (RAD1901 S enantiomer) is an low activity enantiomer of elacestrant. Elacestrant (RAD1901) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.
  • HY-B0216S
    Ethynyl Estradiol-d4

    17α-Ethynylestradiol-d4; Ethynylestradiol-d4

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Ethynyl Estradiol-d4 is the deuterium labeled Ethynyl Estradiol. Ethynyl Estradiol (17α-Ethynylestradiol;Ethynylestradiol) is an orally bio-active estrogen used in almost all modern formulations of combined oral contraceptive pills.
  • HY-B0672S
    Estradiol valerianate-d9

    		Estrogen Receptor/ERR Endocrinology Cancer
    Estradiol valerianate-d9 is the deuterium labeled Estradiol valerianate. Estradiol valerianate (β-estradiol 17-valerate) is a synthetic estrogen widely used in combination with other steroid hormones in hormone replacement therapy drugs.
  • HY-146267
    ERα degrader 5

    		Estrogen Receptor/ERR Cancer
    ERα degrader 5 (Compound 40) is a selective, orally bioavailable estrogen receptor (ER) degrader (SERD) with an EC50 of 1.1 nM against ERα. ERα degrader 5 shows antitumor effect in vivo.
  • HY-W011100
    Cyclofenil

    		Estrogen Receptor/ERR Influenza Virus Infection Endocrinology
    Cyclofenil is a selective estrogen receptor modulator and an ovulation-inducing agent. Cyclofenil shows an inhibitory effect on dengue virus replication in Vero cells with an EC50 of 1.62 μM. Cyclofenil has anti-dengue-virus activity.
  • HY-135590
    Raloxifene 4-Monomethyl Ether

    		Estrogen Receptor/ERR
    Raloxifene 4-Monomethyl Ether (Compound 37) is a Raloxifene derivative that inhibits estrogen receptor α. Raloxifene 4-Monomethyl Ether inhibits MCF-7 cells with an IC50 of 1 μM and a pIC50 of 6.
  • HY-135584
    Raloxifene 6-Monomethyl Ether

    		Estrogen Receptor/ERR
    Raloxifene 6-Monomethyl Ether (Compound 7) is a Raloxifene derivative that inhibits estrogen receptor α. Raloxifene 4-Monomethyl Ether inhibits MCF-7 cells with an IC50 of 250 nM and a pIC50 of 6.6.
  • HY-B0141S
    Estradiol-d3

    β-Estradiol-d3; 17β-Estradiol-d3; 17β-Oestradiol-d3

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estradiol-d3 is the deuterium labeled Estradiol. Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.
  • HY-103447
    Zearalenone

    Mycotoxin F2; Toxin F2

    		 Estrogen Receptor/ERR Others
    Zearalenone is a mycotoxin produced mainly by fungi belonging to the genus Fusarium in foods and feeds. Possess oestrogenic activity in pigs, cattle and sheep, with low acute toxicity. Causes precocious development of mammae and other estrogenic effects in young gilts.
  • HY-107550
    HDAC6-IN-7

    		HDAC Cancer
    TCS HDAC6 20b is a HDAC6-selective inhibitor. TCS HDAC6 20b blocks the growth of estrogen receptor α-positive breast cancer MCF-7 cells.
  • HY-150542
    Steroid sulfatase-IN-2

    		Others Cancer
    Steroid sulfatase -IN-2 is an active steroid sulfatase (STS) inhibitor with an IC50 value of 109.5 nM. Steroid sulfatase-IN-2 can be used for the research of hormone-dependent cancers, such as estrogen-dependent breast and endometrial cancer.
  • HY-148225
    Fulvestrant 3-β-D-Glucuronide

    		Others Cancer
    Fulvestrant 3-β-D-Glucuronide, a metabolite, is glucuronide and sulfate conjugates of Fulvestrant (HY-13636), a pure anti-estrogenic steroid. Fulvestrant 3-β-D-Glucuronide can be used for the research of breast cancer.
  • HY-18719ES
    Endoxifen-d5

    		Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite Cancer
    Endoxifen-d5 is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].
  • HY-N4121
    Isocurcumenol

    		Estrogen Receptor/ERR Apoptosis Cancer
    Isocurcumenol, an estrogen receptor alpha (ERα) inhibitor isolated from Curcuma zedoaria Rhizomes, possesses anti-tumor acticity, with IC50 values of 99.1µg/mL and 178.2 µg/mL in DLA and KB cells, respectively.
  • HY-B0390
    Mestranol

    		Estrogen Receptor/ERR Cancer Endocrinology
    Mestranol is an inactive prodrug and becomes biologically active on conversion to ethinyl estradiol (EE). Mestranol acts as an estrogen receptor agonist. Mestranol combines with a progestin in vivo and can be used for the research of menopausal hormone or menstrual disorders.
  • HY-112100
    PAC

    		Estrogen Receptor/ERR PROTAC-Linker Conjugates for PAC Cancer
    PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
  • HY-B0005A
    Toremifene

    Z-Toremifene; NK 622 free base; FC-1157a free base

    		 Estrogen Receptor/ERR Cancer Infection
    Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively.
  • HY-A0037
    Lasofoxifene

    CP-336156

    		 Estrogen Receptor/ERR Cancer Inflammation/Immunology
    Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis.
  • HY-N7504
    Isopsoralenoside

    		Bacterial Cancer Infection Metabolic Disease
    Isopsoralenoside is a benzofuran glycoside from Psoralea corylifolia. Isopsoralenoside can be quickly metabolized to Psoralen (HY-N0053) in digestive tract contents. Isopsoralenoside show estrogen-like activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity.
  • HY-B0891S
    17α-Hydroxyprogesterone-d8

    17-Hydroxyprogesterone-d8; 17-OHP-d8

    		 Progesterone Receptor Endogenous Metabolite Others
    17α-Hydroxyprogesterone-d8 is the deuterium labeled 17α-Hydroxyprogesterone. 17α-Hydroxyprogesterone (17-Hydroxyprogesterone) is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones, including the corticosteroids and the androgens and the estrogens.
  • HY-121149
    Droloxifene

    3-Hydroxytamoxifen

    		 Estrogen Receptor/ERR Apoptosis Cancer
    Droloxifene, a Tamoxifen derivative, is an orally active and selective estrogen receptor modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats .
  • HY-B0141S2
    Estradiol-d5

    β-Estradiol-d5; 17β-Estradiol-d5; 17β-Oestradiol-d5

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estradiol-d5 is deuterium labeled Estradiol. Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway[1][2][3].
  • HY-B0891S1
    17α-Hydroxyprogesterone-13C3

    17-Hydroxyprogesterone-13C3; 17-OHP-13C3

    		 Progesterone Receptor Endogenous Metabolite Others
    17α-Hydroxyprogesterone- 13C3 is the 13C-labeled 17α-Hydroxyprogesterone. 17α-Hydroxyprogesterone (17-Hydroxyprogesterone) is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones, including the corticosteroids and the androgens and the estrogens.
  • HY-B0141S3
    Estradiol-d2

    β-Estradiol-d2; 17β-Estradiol-d2; 17β-Oestradiol-d2

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estradiol-d2 is the deuterium labeled Estradiol. Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway[1][2][3].
  • HY-B0141S1
    Estradiol-d4

    β-Estradiol-d4; 17β-Estradiol-d4; 17β-Oestradiol-d4

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estradiol-d4 is the deuterium labeled Estradiol. Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway[1][2][3].
  • HY-103454B
    MPP hydrochloride

    		Estrogen Receptor/ERR Apoptosis Cancer Endocrinology
    MPP hydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP hydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP hydrochloride reverses the the positive effects of beta-estradiol. MPP hydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo.
  • HY-109176
    Giredestrant

    GDC-9545

    		 Estrogen Receptor/ERR Cancer
    Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.
  • HY-N9232
    Rutaevin 7-acetate

    		Others Others
    Rutaevin 7-acetate (compound 1) is a limonoid.
  • HY-14590
    Kaempferol

    Kempferol; Robigenin

    		 Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite Cancer
    Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer.
  • HY-124489S1
    2-Hydroxyestradiol-d5

    		Endogenous Metabolite Infection
    2-Hydroxyestradiol-d5 is the deuterium labeled 2-Hydroxyestradiol. 2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity[[1][3][4].
  • HY-108692
    Enterolactone

    		Apoptosis Endogenous Metabolite Cancer
    Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis.
  • HY-B0005
    Toremifene citrate

    Z-Toremifene citrate; NK 622; FC-1157a

    		 Estrogen Receptor/ERR Apoptosis Cancer Infection
    Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively.
  • HY-135903
    Giredestrant tartrate

    GDC-9545 tartrate

    		 Estrogen Receptor/ERR Cancer
    Giredestrant tartrate (GDC-9545 tartrate), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant tartrate potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Anti-tumor activity.
  • HY-124489S
    2-Hydroxyestradiol-13C6

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    2-Hydroxyestradiol- 13C6 is the 13C-labeled 2-Hydroxyestradiol. 2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity[1][3].
  • HY-W250978
    Ovalbumins

    		Endogenous Metabolite Cancer Inflammation/Immunology
    Ovalbumins, the main protein found in egg whites, have various biological activities such as anticancer, antihypertensive, antibacterial, antioxidant and immunomodulatory activities. Ovalbumins are the most abundant proteins synthesized in progesterone- or estrogen-treated fallopian tubes and are commonly used as markers to study hormone control of gene expression in this tissue.
  • HY-B0141S6
    Estradiol-d2-1

    β-Estradiol-d2-1; E2-d2-1; 17β-Estradiol-d2-1; 17β-Oestradiol-d2-1

    		 Estrogen Receptor/ERR Endogenous Metabolite Inflammation/Immunology Neurological Disease
    Estradiol-d2-1 is the deuterium labeled Estradiol. Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway[1][2][3][4].
  • HY-103454
    MPP dihydrochloride

    		Estrogen Receptor/ERR Apoptosis Cancer Endocrinology
    MPP dihydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP dihydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP dihydrochloride reverses the positive effects of beta-estradiol. MPP dihydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo.
  • HY-135309
    PROTAC ER Degrader-4

    		PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ER Degrader-4 is a von Hippel-Lindau-based PROATC estrogen receptor (ER) degrader, binding to ER with an IC50 of 0.8 nM. PROTAC ER Degrader-4 induces ER degradation in MCF-7 cells with an IC50 of 0.3 nM.
  • HY-B0141S4
    Estradiol-13C6

    β-Estradiol-13C6; E2-13C6; 17β-Estradiol-13C6; 17β-Oestradiol-13C6

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estradiol- 13C6 is the 13C-labeled Estradiol. Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway[1][2][3].
  • HY-114154
    AL-438

    		Glucocorticoid Receptor Inflammation/Immunology
    AL-438 is a potent, selective and orally active glucocorticoid receptor modulator with Kis of 2.5, 1786, 53, 1440, >1000 nM for glucocorticoid receptor, progesterone receptor, mineralocorticoid receptor, androgen receptor, estrogen receptor, respectively. AL-438 shows antiinflammatory activity.
  • HY-B0141S5
    Estradiol-13C2

    β-Estradiol-13C2; E2-13C2; 17β-Estradiol-13C2; 17β-Oestradiol-13C2

    		 Estrogen Receptor/ERR Endogenous Metabolite Endocrinology Cancer
    Estradiol- 13C2 is the 13C-labeled Estradiol. Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway[1][2][3].
  • HY-A0038
    Lasofoxifene tartrate

    CP-336156 tartrate

    		 Estrogen Receptor/ERR Endocrinology Cancer
    Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis.
  • HY-144733
    ERα antagonist 1

    		Estrogen Receptor/ERR Apoptosis Cancer
    ERα antagonist 1 (Compound 19d) is a potent, selective, covalent estrogen receptor α (ERα) antagonist. ERα antagonist 1 induces apoptosis and cell cycle G0/G1 phase arrest in MCF-7 cells.
  • HY-150543
    Steroid sulfatase-IN-3

    		Others Cancer
    Steroid sulfatase-IN-3 (compound 1q) is a potent STS (Steroid sulfatase) inhibitor, with an IC50 of 25.8 nM. Steroid sulfatase-IN-3 shows antiproliferative activity against T-47D estrogen-dependent breast cancer cells, with an IC50 of 1.04 µM.
  • HY-B0251S
    Eplerenone-d3

    Epoxymexrenone-d3

    		 Mineralocorticoid Receptor Endogenous Metabolite Cardiovascular Disease
    Eplerenone-d3 is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC50 of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch[1][2].
  • HY-128976
    10β,17β-dihydroxyestra-1,4-dien-3-one

    DHED

    		 Estrogen Receptor/ERR Metabolic Disease
    10β,17β-dihydroxyestra-1,4-dien-3-one (DHED) is a brain-targeting bioprecursor prodrug of the main human estrogen, 17β-estradiol, alleviates hot flushes in rat models of thermoregulatory dysfunction of the brain.
  • HY-B0005AS
    Toremifene-d6

    Z-Toremifene-d6; NK 622-d6 (free base); FC-1157a-d6 (free base)

    		 Estrogen Receptor/ERR Cancer Infection
    Toremifene-d6 is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].
  • HY-B1805
    Triclocarban

    3,4,4′-Trichlorocarbanilide

    		 Bacterial Infection
    Triclocarban (3,4,4′-Trichlorocarbanilide), a broad spectrum antibacterial compound, is widely used in a broad range of applications such as the production of soaps, skin creams, toothpastes and deodorants. Triclocarban is a potential endocrine-disrupting chemical with the capacity to modulate androgen and estrogen activities as well as other hormone-mediated biological processes.
  • HY-B0390S
    Mestranol-d2

    		Estrogen Receptor/ERR Cancer
    Mestranol-d2 is the deuterium labeled Mestranol. Mestranol is an inactive prodrug and becomes biologically active on conversion to ethinyl estradiol (EE). Mestranol acts as an estrogen receptor agonist. Mestranol combines with a progestin in vivo and can be used for the research of menopausal hormone or menstrual disorders[1][2][3].
  • HY-13636
    Fulvestrant

    ICI 182780; ZD 9238; ZM 182780

    		 Estrogen Receptor/ERR Autophagy Apoptosis Cancer
    Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy.
  • HY-129079
    TFMB-(R)-2-HG

    		Others Cancer
    TFMB-(R)-2-HG, a cell membrane-permeable version of (R)-2-HG, is a carcinogenic factor in Acute myeloid leukemia (AML). TFMB-(R)-2-HG impairs SCF ER-Hoxb8 cells differentiation in response to estrogen withdrawal.
  • HY-B0390S1
    Mestranol-d4

    		Estrogen Receptor/ERR
    Mestranol-d4 is the deuterium labeled Mestranol. Mestranol is an inactive prodrug and becomes biologically active on conversion to ethinyl estradiol (EE). Mestranol acts as an estrogen receptor agonist. Mestranol combines with a progestin in vivo and can be used for the research of menopausal hormone or menstrual disorders[1][2][3].
  • HY-144656
    Steroid sulfatase-IN-1

    		Others Cancer
    Steroid sulfatase-IN-1 is a potent and orally active Steroid sulfatase inhibitor with an IC50 of 1.71 µM. Steroid sulfatase-IN-1 shows antitumor activity (TGI=51%) in vivo. Steroid sulfatase-IN-1 has the potential for the research of breast cancer.
  • HY-103453
    (R)-DPN

    		Estrogen Receptor/ERR Endocrinology
    R)-DPN (compound 3) is a selective ERβ ligand with EC50s of 2.9, 0.8 nM for ERα and ERβ, respectively. (R)-DPN shows a very high affinity and potency preference for ERβ over ERα. (R)-DPN shows cytoxicity for HEC-1 and U2OS cells with EC50s of 286, 205 nM, respectively.
  • HY-136186
    (S,R,S)-AHPC-C7-amine

    VH032-C7-amine

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C7-amine (VH032-C7-amine) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERRα) PROTAC degrader.
  • HY-126351
    PROTAC ERRα ligand 2

    		Estrogen Receptor/ERR Cancer
    PROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist with an IC50 of 5.67 nM. PROTAC ERRα ligand 2 (IC50=5.67 nM) displays a ~11-fold improved potency than XCT790 (IC50=61.3 nM).
  • HY-145572
    Imlunestrant

    LY-3484356

    		 Estrogen Receptor/ERR Cancer
    Imlunestrant (LY-3484356) is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC).
  • HY-145572A
    Imlunestrant tosylate

    LY-3484356 tosylate

    		 Estrogen Receptor/ERR Cancer
    Imlunestrant (LY-3484356) tosylate is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant tosylate results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant tosylate can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC).
  • HY-14248S
    Letrozole-d4

    		Cytochrome P450 Isotope-Labeled Compounds Autophagy Cancer
    Letrozole-d4 (CGS 20267-d4) is the deuterium labeled Letrozole. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer[1][2][3].
  • HY-135671
    AhR modulator-1

    		Aryl Hydrocarbon Receptor VEGFR Estrogen Receptor/ERR Cancer Endocrinology
    AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus.
  • HY-128527
    PROTAC ER Degrader-3

    		PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
  • HY-108692S
    Enterolactone-d6

    		Apoptosis Endogenous Metabolite Cancer
    Enterolactone-d6 is the deuterium labeled Enterolactone. Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity[1]. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis[2].
  • HY-128528
    PROTAC ER Degrader-2

    		PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
  • HY-B0005S
    Toremifene-d6 citrate

    		Estrogen Receptor/ERR Apoptosis Cancer Infection
    Toremifene-d6 (citrate) is the deuterium labeled Toremifene citrate. Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].
  • HY-10426
    XCT790

    		Estrogen Receptor/ERR Autophagy Cancer
    XCT-790 is a potent and selective inverse agonist for ERRα with an IC50 value of 0.37 μM. XCT-790 induces cell death in chemotherapeutic resistant cancer cells. XCT-790 (Compound 12) is inactive against ERRγ and the estrogen receptors ERα and ERβ.
  • HY-N0367
    Trans-Anethole

    (E)​-Anethole

    		 Endogenous Metabolite Endocrinology Cancer
    Trans-Anethole ((E)-Anethole), a phenylpropene derivative isolated from Foeniculum vulgare, shows estrogenic activity at lower concentrations and cytotoxic at higher concentrations in cancer cell lines. Trans-Anethole ((E)-Anethole) contributes a large component of the odor and flavor of anise and fennel, anise myrtle, liquorice, camphor, magnolia blossoms, and star anise.
  • HY-111226
    GSK5182

    		Estrogen Receptor/ERR Reactive Oxygen Species Cancer Cardiovascular Disease
    GSK5182 is a highly selective and orally active inverse agonist of estrogen-related receptor γ (ERRγ) with an IC50 of 79 nM. GSK5182 does not interact with other nuclear receptors, including ERRα or ERα. GSK5182 also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma (HCC).
  • HY-133017
    Amcenestrant

    SAR439859

    		 Estrogen Receptor/ERR Cancer
    SAR439859 (compound 43d) is an orally active, nonsteroidal and selective estrogen receptor degrader (SERD). SAR439859 is a potent ER antagonist and has ER degrading activity with an EC50 of 0.2 nM for ERα degradation. SAR439859 demonstrates robust antitumor efficacy and limited cross-resistance in ER + breast cancer.
  • HY-N10403
    4-Hydroxyestradiol

    4-Hydroxy-17β-estradiol

    		 Drug Metabolite Endogenous Metabolite Cancer
    4-Hydroxyestradiol (4-Hydroxy-17β-estradiol) is an endogenous metabolite of Estradiol (HY-B0141). 4-Hydroxyestradiol is carcinogenic and shows mutagenic activity in breast epithelial cells. 4-Hydroxyestradiol inhibits the binding of Estradiol to the estrogen receptor in a competitive manner, with a Ki of 0.48 nM.
  • HY-112098
    PROTAC ERα Degrader-1

    		PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha (ERα) degrader.
  • HY-132294A
    (1S,3R)-GNE-502

    		Estrogen Receptor/ERR Cancer
    (1S,3R)-GNE-502 (compound 179) is a potent ERα degrader with an EC50 value of 13 nM against ERα in MCF7 HCS. (1S,3R)-GNE-502 can be used to research cancer related with estrogen receptor.
  • HY-132194
    ERα degrader-2

    		Estrogen Receptor/ERR Cancer
    ERα degrader-2 is a selective estrogen receptor degrader (SERD) with potent binding affinity with ERα (IC50=17.1 nM), good degradation efficacy (EC50=0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent druggability, can be used for HER + breast cancer research.
  • HY-136187
    (S,R,S)-AHPC-C5-NH2

    VH032-C5-NH2

    		 E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-C5-NH2 (VH032-C5-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERRα) PROTAC degrader.
  • HY-13636S
    Fulvestrant-d3

    ICI 182780-d3; ZD 9238-d3; ZM 182780-d3

    		 Estrogen Receptor/ERR Autophagy Apoptosis Cancer
    Fulvestrant-d3 is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy[1].
  • HY-143439
    LX-039

    		Estrogen Receptor/ERR Cancer
    LX-039 is a highly potent, selective and orally active estrogen receptor degrader with EC50 value of 2.29 nM. LX-039 has indole C-3 chlorine atom. LX-039 exhibits excellent mouse pharmacokinetics, low clearance, high Cmax and oral exposure. LX-039 has anti-tumor activity.
  • HY-N6052
    (+)-Medicarpin

    		Estrogen Receptor/ERR Cancer
    (+)-Medicarpin, a pterocarpan, is a type of isoflavonoid isolated from several medicinal plant species with various biological effects, including Sophora japonica, Zollernia paraensis and Platymiscium yucatamun, Machaerium aristulatum, Platymiscium floribundum, and so on. (+)-Medicarpin potently inhibits osteoclastogenesis and promotes bone healing and increases bone mass by osteoblast differentiation with estrogen receptor (ER) β-mediated osteogenic action.
  • HY-110193
    SPP-86

    		RET Cancer
    SPP-86 is a potent and selective cell permeable inhibitor of RET tyrosine kinase, with an IC50 of 8 nM. SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells.
  • HY-B1805S
    Triclocarban-d4

    3,4,4′-Trichlorocarbanilide-d4

    		 Bacterial Infection
    Triclocarban-d4 is the deuterium labeled Triclocarban. Triclocarban (3,4,4′-Trichlorocarbanilide), a broad spectrum antibacterial compound, is widely used in a broad range of applications such as the production of soaps, skin creams, toothpastes and deodorants. Triclocarban is a potential endocrine-disrupting chemical with the capacity to modulate androgen and estrogen activities as well as other hormone-mediated biological processes[1][2][3].
  • HY-144699
    ERRα antagonist-2

    		Estrogen Receptor/ERR Cancer
    ERRα antagonist-2 (Compound 11) is a potential ERRα (estrogen related receptor α) inverse agonist with an IC50 of 0.80 μM. ERRα antagonist-2 suppresses the migration and invasion of the ER-negative MDA-MB-231 cell line. ERRα antagonist-2 inhibits breast cancer growth in vivo.
  • HY-N7503
    Psoralenoside

    		Histamine Receptor Calcium Channel Calmodulin Cancer Infection Metabolic Disease
    Psoralenoside is a benzofuran glycoside from Psoralea corylifolia. Psoralenoside exhibits high binding affinities against histaminergic H1, calmodulin, and voltage-gated L-type calcium channels (E-value≥-6.5 Kcal/mol). Psoralenoside shows estrogen-like activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity.
  • HY-111226A
    (E/Z)-GSK5182

    		Estrogen Receptor/ERR Reactive Oxygen Species Cancer Cardiovascular Disease
    (E/Z)-GSK5182 is a racemic compound of (E)-GSK5182 and (Z)-GSK5182 isomers. GSK5182 is a highly selective and orally active inverse agonist of estrogen-related receptor γ (ERRγ) with an IC50 of 79 nM. GSK5182 also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma.
  • HY-N0322
    Cholesterol

    		Liposome Estrogen Receptor/ERR Endogenous Metabolite Bacterial Metabolic Disease Cancer
    Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist.
  • HY-50767C
    Palbociclib hydrochloride

    PD-0332991 hydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
  • HY-151749
    N3-D-Lys(Fmoc)-OH

    		ADC Linker Others
    N3-D-Lys(Fmoc)-OH is a click chemistry reagent containing an azide group. Click chemistry is a powerful chemical reaction with excellent bioorthogonality features: biocompatible, rapid and highly specific in biological environments.
  • HY-50767B
    Palbociclib dihydrochloride

    PD-0332991 dihydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) dihydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib dihydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
  • HY-151736
    N3-L-Dap(Boc)-OH

    		ADC Linker Others
    N3-L-Dap(Boc)-OH is a click chemistry reagent containing an azide group. Click chemistry is a powerful chemical reaction with excellent bioorthogonality features: biocompatible, rapid and highly specific in biological environments.
  • HY-50767
    Palbociclib

    PD 0332991

    		 CDK Cancer
    Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
  • HY-50767D
    Palbociclib orotate

    PD 0332991 orotate

    		 CDK Cancer
    Palbociclib (PD 0332991) orotate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib orotate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib orotate can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
  • HY-151747
    Chemical phosphorylation amidite

    		ADC Linker Others
    Chemical phosphorylation amidite is a click chemistry reagent containing an azide group. Click chemistry is a powerful chemical reaction with excellent bioorthogonality features: biocompatible, rapid and highly specific in biological environments.
  • HY-50767A
    Palbociclib monohydrochloride

    PD 0332991 monohydrochloride

    		 CDK Cancer
    Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
  • HY-A0065
    Palbociclib isethionate

    PD 0332991 isethionate

    		 CDK Cancer
    Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
  • HY-130499
    ERRα Ligand-Linker Conjugates 1

    		Target Protein Ligand-Linker Conjugates Cancer
    ERRα Ligand-Linker Conjugates 1 incorporates a ligand for estrogen-related receptor alpha (ERRα), and a PROTAC linker, which recruit E3 ligases MDM2. ERRα Ligand-Linker Conjugates 1 can be used in the synthesis of a series of PROTACs, such as PROTAC ERRalpha Degrader-1 (HY-128838). PROTAC ERRalpha Degrader-1 is an ERRα degrader.
  • HY-16023A
    Acolbifene

    EM-652; SCH 57068

    		 Estrogen Receptor/ERR Cancer
    Acolbifene (EM-652), the active metabolite of EM800, is an orally active pure antiestrogen and selective estrogen receptor antagonist. Acolbifene (EM-652) inhibits estradiol (E2)-induced transcriptional activity of ERα (IC50 = 2 nM) and ERβ (IC50 = 0.4 nM). Acolbifene (EM-652) possesses potent and pure anticarcinogenic properties.
  • HY-128600
    ERD-308

    		PROTACs Estrogen Receptor/ERR Cancer
    ERD-308 is a highly potent von Hippel-Lindau-based PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively).
  • HY-135594
    4'-Raloxifene-β-D-glucopyranoside

    		Estrogen Receptor/ERR Metabolic Disease
    4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A.
  • HY-135595
    6-Raloxifene-β-D-glucopyranoside

    		Estrogen Receptor/ERR Drug Metabolite Metabolic Disease
    6-Raloxifene-β-D-glucopyranoside, a derivative of Raloxifene, is a benzothiophene glucuronidated at the 6' postion. 6-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 6'-Raloxifene-β-D-glucopyranoside, compound Ia, is extracted from patent US5567820A.
  • HY-146440
    LSD1/ER-IN-1

    		Histone Demethylase Estrogen Receptor/ERR Apoptosis Cancer
    LSD1/ER-IN-1 (compound 11g) is a potent ER and LSD1 inhibitor, with an IC50 of 1.55 μM (LSD1). LSD1/ER-IN-1 has high affinity selectivity for ERα protein, with α/β ratio of 7.11. LSD1/ER-IN-1 shows good antiproliferative activity against MCF-7 breast cancer cells, with an IC50 of 8.79 μM.
  • HY-N0322S8
    Cholesterol-18O

    		Estrogen Receptor/ERR Endogenous Metabolite
    Cholesterol- 18O is the deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3][4].
  • HY-N0322S7
    Cholesterol-d1

    		Estrogen Receptor/ERR Endogenous Metabolite
    Cholesterol-d is the deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3][4].
  • HY-N0322S
    Cholesterol-d7

    		Estrogen Receptor/ERR Endogenous Metabolite Metabolic Disease
    Cholesterol-d7 is the deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3].
  • HY-132205
    DS45500853

    		Estrogen Receptor/ERR Metabolic Disease
    DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM).
  • HY-N0322S1
    Cholesterol-d6

    		Estrogen Receptor/ERR Endogenous Metabolite
    Cholesterol-d6 is the deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3][4].
  • HY-111846
    PROTAC ERα Degrader-2

    		SNIPERs PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ERα Degrader-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).
  • HY-N0322S6
    Cholesterol-d4

    		Estrogen Receptor/ERR Endogenous Metabolite Metabolic Disease
    Cholesterol-d4 is deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3].
  • HY-14933
    Prinaberel

    ERB-041

    		 Estrogen Receptor/ERR Wnt Apoptosis Cancer
    Prinaberel (ERB-041) is a potent and selective estrogen receptor (ER) β agonist with IC50s of 5.4, 3.1 and 3.7 nM for human, rat and mouse ERβ, respectively. Prinaberel displays >200-fold selectivity for ERβ over ERα. Prinaberel is a potent skin cancer chemopreventive agent that acts by dampening the WNT/β-catenin signaling pathway. Prinaberel induces ovarian cancer apoptosis.
  • HY-A0031S
    Bazedoxifene-d4

    TSE-424-d4

    		 Estrogen Receptor/ERR Cancer
    Bazedoxifene-d4 is deuterium labeled Bazedoxifene. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].
  • HY-N0322S2
    Cholesterol-d6-1

    		Estrogen Receptor/ERR Endogenous Metabolite Metabolic Disease
    Cholesterol-d6-1 is the deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3].
  • HY-145071
    PROTAC ERα Y537S degrader-1

    		PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ERα Y537S degrader-1 comprises a ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Y537S degrader-1 extracts from patent WO2021143822, example 12. PROTAC ERα Y537S degrader-1 is an estrogen receptor-alpha (ERα) Y537S degrader.
  • HY-N0322S5
    Cholesterol-13C2

    		Estrogen Receptor/ERR Endogenous Metabolite Metabolic Disease
    Cholesterol- 13C2 is the 13C labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3].
  • HY-A0031S2
    Bazedoxifene-d4 acetate

    TSE-424-d4 acetate

    		 Estrogen Receptor/ERR Cancer
    Bazedoxifene-d4 (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].
  • HY-143201
    DS20362725

    		Estrogen Receptor/ERR Metabolic Disease
    DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM).
  • HY-144306
    ERα degrader 4

    		Estrogen Receptor/ERR Apoptosis Cancer
    ERα degrader 4 is an excellent and selective estrogen receptor α (ERα) degrader (IC50 of 0.31, 0.41 and 0.48 μM in MDA-MB-231, MCF-7 and MCF-7/ADR cells, respectively). ERα degrader 4 has potent inhibitory activity against MCF-7 cell lines. ERα degrader 4 is a potential SERDs candidate for the treatment of breast cancer.
  • HY-N0322S4
    Cholesterol-13C3

    		Estrogen Receptor/ERR Endogenous Metabolite Metabolic Disease
    Cholesterol- 13C3 is the 13C-labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3].
  • HY-112611
    H3B-5942

    		Estrogen Receptor/ERR Cancer
    H3B-5942 is a selective, irreversible and orally active estrogen receptor covalent antagonist, inactivates both wild-type and mutant ERα by targeting Cys530, with Kis of 1 nM and 0.41 nM, respectively. H3B-5942 reduces ERα target gene GREB1, shows potent antitumor activity both in multiple cell lines or animals bearing ERα WT or ERα mutations.
  • HY-N0322S3
    Cholesterol-13C5

    		Estrogen Receptor/ERR Endogenous Metabolite Metabolic Disease
    Cholesterol- 13C5 is the 13C-labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3].
  • HY-105118A
    Zaldaride maleate

    CGS-9343B; KW 5617

    		 nAChR Metabolic Disease Inflammation/Immunology Neurological Disease
    Zaldaride maleate (CGS-9343B) is a potent, orally active and selective inhibitor of calmodulin. Zaldaride maleate (CGS-9343B) inhibits CaM (calmodulin)-stimulated cAMP phosphodiesterase activity, with an IC50 of 3.3 nM. Zaldaride maleate (CGS-9343B) prevents estrogen-induced transcription activation by ER, reversibly blocks voltage-activated Na +, Ca 2+ and K + currents in PC12 cells and inhibits nAChR.
  • HY-16023
    Acolbifene hydrochloride

    EM-652 hydrochloride; SCH 57068 hydrochloride

    		 Estrogen Receptor/ERR Cancer
    Acolbifene (EM-652) hydrochloride, an active metabolite of EM800, is an orally active, cancer-preventing selective estrogen receptor modulator (SERM). Acolbifene (EM-652) hydrochloride inhibits estradiol (E2)-induced transcriptional activity of ERα (IC50=2 nM) and ERβ (IC50=0.4 nM). Acolbifene (EM-652) hydrochloride exerts a potent and pure antiestrogenic action in the mammary gland and uterus. Anticarcinogenic properties.
  • HY-129619
    SNIPER(ER)-87

    		SNIPERs Estrogen Receptor/ERR Cancer
    SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor α (ERα) ligand 4-hydroxytamoxifen by a PEG linker, and efficiently degrades the ERα protein (IC50=0.097 μM). SNIPER(ER)-87 preferentially recruits XIAP to ERα in the cells, and XIAP is the primary E3 ubiquitin ligase responsible for the SNIPER(ER)-87-induced ERα degradation.
  • HY-B0141
    Estradiol

    β-Estradiol; E2; 17β-Estradiol; 17β-Oestradiol

    		 Estrogen Receptor/ERR Endogenous Metabolite Bacterial Endocrinology Cancer
    Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
  • HY-B0141C
    Estradiol hemihydrate

    β-Estradiol hemihydrate; 17β-Estradiol hemihydrate; 17β-Oestradiol hemihydrate

    		 Estrogen Receptor/ERR Endogenous Metabolite Bacterial Cancer Neurological Disease
    Estradiol (β-Estradiol) hemihydrate is a steroid hormone and the major female sex hormone. Estradiol (β-Estradiol) hemihydrate can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol (β-Estradiol) hemihydrate can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
  • HY-151201
    Steroid sulfatase/17β-HSD1-IN-3

    		Others Cancer
    Steroid sulfatase/17β-HSD1-IN-3 (compound 19) is a dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). Steroid sulfatase/17β-HSD1-IN-3 irreversibly inhibits hSTS activity with anIC50 value of 27 nM. Steroid sulfatase/17β-HSD1-IN-3 can be used in the study of endometriosis and other estrogen-dependent diseases.
  • HY-151202
    Steroid sulfatase/17β-HSD1-IN-4

    		Others Cancer
    Steroid sulfatase/17β-HSD1-IN-4 (compound 37) is a dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). Steroid sulfatase/17β-HSD1-IN-4 irreversibly inhibits hSTS activity with anIC50 value of 63 nM. Steroid sulfatase/17β-HSD1-IN-4 can be used in the study of endometriosis and other estrogen-dependent diseases.
  • HY-N1940
    β-Anhydroicaritin

    		Interleukin Related TNF Receptor MMP Inflammation/Immunology
    β-Anhydroicaritin is isolated from Boswellia carterii Birdware, has important biological and pharmacological effects, such as antiosteoporosis, estrogen regulation and antitumor properties. β-Anhydroicaritin ameliorates the degradation of periodontal tissue and inhibits the synthesis and secretion of TNF-α and MMP-3 in diabetic rats. β-Anhydroicaritin decreases the overproduction of NO, IL-10, TNF-α, MCP-1 and IL-6 in inperitonitis mice. β-Anhydroicaritin inhibits the elevation of intracellular Ca 2+, and markedly decreases iNOS protein expression.
  • HY-119539
    Limocitrin

    		Phosphatase Cancer Endocrinology
    Limocitrin is a natural product that can be isolated from the buds of P. acerifolia and P. orientalis. Limocitrin suppresses estradiol-dependent proliferation of MCF7 cells weakly but estradiol-induced AlkP (alkaline phosphatase) expression only marginally.
  • HY-113960
    ERRα antagonist-1

    		Estrogen Receptor/ERR Cancer
    ERRα antagonist-1 (Compound A) is a selective and high affinity estrogen-related receptor α (ERRα) antagonist. ERRα antagonist-1 inhibits interaction of ERRα with Proliferator-activated Receptor γ Coactivator-1α (PGC-1α) and PGC-1β, the IC50 values are 170 nM and 180 nM, respectively. ERRα antagonist-1 does not inhibit the interaction of either ERRβ or ERRγ with PGC-1α and PGC-1β coactivator, and also does not inhibit interaction of ERα or ERβ with PGC-1α or SRC-1.